Mesothelioma Chemotherapy, Cisplatin and Carboplatin

A mesothelioma article recently published in scientific journals Lung Cancer that examined the benefits and costs with a combination of Cisplatin and Carboplatin and Pemetrexed Pemetrexed for mesothelioma chemotherapy.

PA Photo Asbestos Exposure Mesothelioma Chemotherapy combination of Cisplatin and Pemetrexed is one of several chemotherapy options that have proven successful enough to handle patients with malignant pleural mesothelioma / malignant pleural mesothelioma (MPM), but this combination can be very toxic to the body. There is no cure and treatments for malignant mesothelioma cancer without undesirable side effects.

In the journal the researchers noted that "there are two phases of a randomized study in Phase III shows the benefits for the prognosis of mesothelioma with the use of antifolates such as raltitrexed or pemetrexed, when combined with cisplatin. The study has shown an absolute improvement in overall survival an average of 2.6 and 2.8 months, compared with single treatment for cisplatin. This makes a lot of institutions using cisplatin and pemetrexed as the standard palliative chemotherapy treatment for malignant pleural mesothelioma. "

Unfortunately, the combination of cisplatin and pemetrexed produces unwanted toxic effects and it encourages researchers to study other chemotherapy drugs to be combined with pemetrexed. Researchers said, "Recently, two phase II trials have evaluated the efficacy of Carboplatin and pemetrexed in MPM. Both studies showed overall response rate of 18.6 and 25%, with a survival rate of 12.7 and an average of 14 months. Following on from these results, we have undertaken a retrospective analysis in patients with MPM treated with Carboplatin and Pemetrexed in our institution. "

In an effort to find a combination chemotherapy of mesothelioma with minimal toxicity and side effects, the researchers investigated further by replacing Cisplatin with Carboplatin when paired with Pemetrexed. Using a retrospective approach, researchers evaluated 49 cases of malignant pleural mesothelioma who were given a combination of Carboplatin and Pemetrexed and compare the results with data of cisplatin combination chemotherapy with Pemetrexed.

Level of disease control (known in the absence of progressive signs of mesothelioma over CT scan) for patients was 69 percent, and the percentage of partial response and stable disease by 28 percent and 41 percent. Clinical improvement is shown in figure 69 percent, the majority of patients reported an increase in profits after two cycles of chemotherapy. Toxicity is generally low and better than the toxicity of cisplatin with pemetrexed.

The average time to treatment failure was 4.6 months. The average overall survival in this study is 14 months, compared with the cisplatin-pemetrexed for 12.1 months. The authors suggested, "In conclusion, our data show a combination of Carboplatin and Pemetrexed may be an option in the treatment of mesothelioma, particularly in patients who experience problems with the use of cisplatin."

Xtreme Fat Loss Diet System!